- Patients
- Clinical Research
- Clinical trials
- ASCENT-04
2022-07-17T00:00:00.000+10:00
Ongoing
ASCENT 04
ASCENT 04
Breast cancer
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients with Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumours Express PD-L1
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients with Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumours Express PD-L1
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Breast
Study Phase
III |
Trial Identifiers
Registration number: NCT05382286 https://clinicaltrials.gov/study/NCT05382286
|
GenesisCare Location(s)
GenesisCare North Shore
GenesisCare North Shore
:::
Principal Investigator(s)